TriSalus Life Sciences, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
TriSalus amended its credit facility with OrbiMed (fifth amendment, May 28, 2026) revising product revenue targets upward through Dec 2026 and beyond ($50M recurring baseline); paid $350k amendment fee. Separately, Dr. Richard Marshall hired as Chief Medical Officer (March 30, 2026 effective) at $525k base salary, up to 50% annual bonus, $250k annual sign-on bonus for 2 years, standard non-compete/confidentiality, 2-year initial term with auto-renewal, and change-of-control severance provisions.
Why this rating
Credit amendment is routine debt management (0.31% of market cap). CMO hire is normal exec hiring. No material financial impact disclosed; moderate operational significance only.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.